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Sharing of clinical trial data and research integrity 
Imagine that you went to see your family physician with an ailment, and she/he prescribed some medication. After taking it, you devel-
oped a nasty reaction, were hospitalized and learned only there and then 
(if ever) that you should not have been prescribed this particular medi-
cation given your other conditions, age or sex. How could that happen? 
Well, chances are your doctor did not have access to all the information 
about the medicines prescribed. Oops! Or imagine that you are a re-
searcher who spent a few years preparing a study to test a promising new 
medicine. You then started the clinical trial, and your study participants 
experienced no effects or serious side-effects. Only then did you learn 
(if ever) that this particular intervention had proven to be unsuccessful 
or even harmful in several unreported or currently ongoing studies that 
you were unaware of. Thus, you wasted several years on a useless or 
potentially harmful study.
Clinical trials* are indispensable in the development of most new and 
improved medical interventions (1). Integrity in clinical trials seems to 
be difficult to achieve due to numerous barriers, including the culture 
of non-sharing of research data. I argue that full transparency of clinical 
trial data is an essential prerequisite to achieving research integrity, and 
is equally important as factors such as the initial idea, a high quality 
research plan and protocol, and the ethically sound conduct of research.
In the health field, we (cl)aim to make evidence-informed decisions. 
This would be phenomenal provided we had reliable evidence; evidence 
based on all knowledge available at a given moment in time. However, 
we don�t. Evidence gained by systematic review, meta-analysis of ag-
gregate data and pooled analysis of raw data of clinical trials is consid-
ered to be the most reliable evidence we can devise for health care deci-
sion-making, including for the development of new diagnostics and 
therapies.
Research is continuously getting more powerful largely due to new 
technologies and related know-how. It benefits from the ever-increasing 
possibilities offered by digital and cloud-based software technologies, 
including electronic data management and record keeping that should 
have enabled faster knowledge creation, and a higher level of efficiency 
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*Clinical trials (also known as interventional studies) are performed on human 
participants, which can be either healthy volunteers or individuals that suffer from 
a disease or condition for which diagnostic procedures or therapies are being devel-
oped. The intervention, for example, could be that a candidate for a new drug is 
given to study participants and its effects are measured and compared to the existing 
medication or to the placebo if there is no existing medication.
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and integrity of research. Alas, this has been true only to 
a degree: clinical trial research is burdened with various 
biases that arise from the non-sharing of research data (1). 
Research, especially health research, seems to be a hostage 
to the existing, more or less unchanged fear of sharing 
data, and of the “it’s mine” and “no data sharing until 
there is clear and unambiguous proof that no harm will 
result (especially to me)” culture viewpoint (2). In short, 
research paradigm changes lag behind the advancements 
of technology. 
Numerous benefits are anticipated from increasing the 
sharing of clinical research data: it accelerates the develop-
ment of new knowledge and innovation, enhances trans-
lational research, informs decision-making and helps 
ensure the efficiency and integrity of research. Specific 
benefits include avoiding unnecessary and redundant re-
search and thus decreasing the burden on research par-
ticipants. On the other hand, there is increased awareness 
of the harm caused by the non-sharing or partial sharing 
of such data.
I want to believe that researchers aim to perform 
meaningful and efficient research, which is ethically and 
economically sound and contributes to the common 
good. Thus I expect that any given researcher would take 
advantage of existing tools to develop, conduct, and re-
port high quality and efficient trials. These tools include 
systematic reviews to capture the existing knowledge, 
SPIRIT guidelines (3) for protocol development, ethics 
approvals guaranteeing the respect of study participants’ 
wellbeing, and CONSORT guidelines (4) for the publica-
tion of summaries of findings. 
WHO International standards define trial registration, 
and its International Clinical Trials Registry Platform 
links to the basic protocol information hosted by a net-
work of WHO trial registries. One of these registries, 
Clinicaltrials.gov, also accepts results in aggregate data 
format. Supported by journal editors (5, 6), funders, the 
Ottawa group, All Trials initiative and others, and en-
forced by national legislations, trial registration is gradu-
ally becoming an integral part of the clinical trial process.
The next step is to complement trial registration with 
results disclosure, publication of findings and public dis-
closure of all data, including raw data; i.e. individual par-
ticipant data (IPD). However, although there are reposi-
tories that host clinical trial data, the methodology for 
preparation of data for public release and reuse is still 
under development and no standards exist. Researchers 
need to know what the analysable data set consists of and 
where to deposit it, which calls for the development of 
methodology and standards to guide data preparation for 
public release and re-analysis. Such datasets would in-
clude anonymized IPD, metadata, dictionary (descrip-
tors) and more; presented in a structured format, which 
should follow certain standards across repositories. 
Initiatives aimed at opening clinical trial data have 
been taking place in many parts of the world in various 
forms (7, 8). The strength of this movement is that it 
brings together people from various fields, including data 
managers, scientists and knowledge users.
The abundance of research and the benefits that re-
searchers seek from it have led to increased concerns for 
research integrity and responsible research. There are nu-
merous scientific, practical, legal and ethical issues that 
prevent the achievement of fully responsible and efficient 
research. Physician clinical trialists are also bound by the 
Hippocratic Oath and its “do no harm” principle, as well 
as the promise that “the health of my patient will be my 
first consideration…” The Declaration of Helsinki (9) is 
increasingly calling for trial registration and sharing of 
results, as is the World Health Organization. Offices of 
research integrity have been formed, and the World Con-
ference on Research Integrity produces statements aiming 
at increasing the integrity in research. An issue of par-
ticular concern is that of data sharing. Public disclosure 
of data would not only facilitate the verification of pub-
lished information and increase the speed of knowledge 
creation, but it would also contribute to the prevention of 
other research integrity issues such as plagiarism and 
fraud.
Interest in broader sharing of research data is increas-
ing and many initiatives are underway. In the clinical 
trial field, notable recent efforts include the US Institute 
of Medicine (IOM) recommendations  on sharing clinical 
trial data (10), the European Clinical Trial Regulations 
(11) as well as policies of the European Medicine Agency 
(EMA) (12) that will enable access to clinical trial reports 
as of January 2015. Many, including the Ottawa Group 
and its IMPACT Initiative, are looking for methods and 
standards for the public disclosure of trial data and re-
lated repositories.
The field is so complex that it would merit structured 
monitoring of the impact of changes in data sharing on 
clinical trials in order to connect dots and indicate trends. 
The recently started IMPACT Observatory (natural ex-
periment) aims to do just that. 
Overall understanding of the advantages of open data 
and open science is increasing. New technological op-
portunities are enabling the analysis of big data sets with 
new algorithms. This does not only serve the purpose of 
verifying whether a report is biased, but the reanalysis of 
several trials can lead to more findings. The clinical trial 
field is not isolated in this evolution of research; it could 
learn a lot from other areas as many are more advanced. 
However, there is insufficient communication of experi-
ence with data sharing among scientific fields, which 
again might be due to its novelty and dynamics. 
The opening of oncology clinical trials data is particu-
larly important as it would contribute to the desperately 
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needed increase in knowledge and innovation, which is 
essential to in the fight against cancer. One example of 
data sharing initiatives in oncology is the CEO Round-
table on Cancer and its Project DataSphere (PDS) as it 
aims to brings together private, public and not-for-profit 
organizations to fight cancer. In 2014, following several 
years of preparation, the CEO launched the DataSphere 
platform of oncology with the goal of gradually making 
oncology data available for further research, to “share, 
integrate and analyse” and thus speed up the development 
of new therapies. 
The vast majority of clinical research data is still not 
open but rather is of limited access, including semi-open 
data sharing, sharing within certain groups, sharing pre-
competitive data only, and sharing for research purposes 
only, upon request or by agreement. 
The opening of clinical trial data would enhance the 
efficiency and responsibility of research, and contribute 
to strengthening or even regaining people’s trust in re-
search and medicine. It has been emphasized over and 
over again that we have to do whatever it takes to over-
come the remaining barriers in opening clinical trial data 
as we primarily owe it to trial participants. After all, they 
are the ones who take a risk by participating in the clini-
cal trials that enable data gathering to begin with.
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